Dianthus Therapeutics (NASDAQ:DNTH) EVP Sells $230,848.54 in Stock

Key Points

• EVP Ryan Savitz sold 2,561 Dianthus Therapeutics shares for about $230,849 at an average price of $90.14, reducing his direct holdings by 8.04% to 29,276 shares.
• DNTH shares rose 3.6% to $92.48 on Thursday. The company’s latest quarterly loss per share was narrower than analysts expected, and revenue exceeded estimates.
• Analysts hold a broadly positive view: the stock has an average “Buy” rating and a consensus price target of $128.77.

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) EVP Ryan Savitz sold 2,561 shares of the company's stock in a transaction on Tuesday, November 10th. The shares were sold at an average price of $90.14, for a total value of $230,848.54. Following the completion of the transaction, the executive vice president directly owned 29,276 shares in the company, valued at approximately $2,638,938.64. This represents a 8.04% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Ryan Savitz also recently made the following trade(s):

• On Wednesday, November 11th, Ryan Savitz sold 3,044 shares of Dianthus Therapeutics stock. The stock was sold at an average price of $90.03, for a total value of $274,051.32.
• On Thursday, November 12th, Ryan Savitz sold 17,724 shares of Dianthus Therapeutics stock. The stock was sold at an average price of $90.56, for a total value of $1,605,085.44.
• On Monday, November 9th, Ryan Savitz sold 100,713 shares of Dianthus Therapeutics stock. The shares were sold at an average price of $90.54, for a total transaction of $9,118,555.02.

Dianthus Therapeutics Stock Up 3.6%

Shares of Dianthus Therapeutics stock traded up $3.18 during trading on Thursday, reaching $92.48. The company's stock had a trading volume of 921,016 shares, compared to its average volume of 931,449. The business's 50-day moving average price is $89.05 and its 200-day moving average price is $86.15. The firm has a market cap of $5.21 billion, a PE ratio of -23.18 and a beta of 1.47. Dianthus Therapeutics, Inc. has a 52 week low of $34.29 and a 52 week high of $117.88.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last released its quarterly earnings results on Wednesday, November 4th. The company reported ($0.81) EPS for the quarter, topping analysts' consensus estimates of ($0.94) by $0.13. Dianthus Therapeutics had a negative net margin of 7,436.50% and a negative return on equity of 19.68%. The business had revenue of $1.21 million for the quarter, compared to analyst estimates of $0.46 million. Equities analysts predict that Dianthus Therapeutics, Inc. will post -3.55 earnings per share for the current year.

Hedge Funds Weigh In On Dianthus Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of DNTH. Walleye Capital LLC bought a new stake in shares of Dianthus Therapeutics during the second quarter worth about $1,743,000. SummitTX Capital L.P. increased its stake in shares of Dianthus Therapeutics by 13.8% in the first quarter. SummitTX Capital L.P. now owns 100,044 shares of the company's stock valued at $8,396,000 after buying an additional 12,118 shares during the period. California State Teachers Retirement System increased its stake in shares of Dianthus Therapeutics by 155.5% in the first quarter. California State Teachers Retirement System now owns 40,584 shares of the company's stock valued at $3,406,000 after buying an additional 24,697 shares during the period. Bank of America Corp DE bought a new position in Dianthus Therapeutics in the 2nd quarter valued at approximately $25,036,000. Finally, Spruce Street Capital LP bought a new position in Dianthus Therapeutics in the 2nd quarter valued at approximately $34,587,464. Institutional investors and hedge funds own 47.53% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the company. Wedbush upped their target price on Dianthus Therapeutics from $105.00 to $122.00 and gave the company an "outperform" rating in a research report on Wednesday, August 5th. JPMorgan Chase & Co. initiated coverage on Dianthus Therapeutics in a research report on Friday, September 11th. They issued an "overweight" rating and a $135.00 price target on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $158.00 price target on shares of Dianthus Therapeutics in a research note on Thursday, October 15th. Truist Financial upped their price objective on shares of Dianthus Therapeutics from $110.00 to $128.00 and gave the stock a "buy" rating in a research report on Thursday, August 6th. Finally, Roth Capital began coverage on shares of Dianthus Therapeutics in a research note on Tuesday, October 27th. They set a "buy" rating and a $113.00 price objective on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $128.77.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics is a clinical-stage biotechnology company developing medicines for autoimmune and inflammatory diseases involving the complement system, a part of the immune system. The company's research focuses on selectively targeting complement activity that contributes to disease. Dianthus became a publicly traded company in 2023 through a merger with Magenta Therapeutics. Its clinical development activities are intended to support potential use across patient populations, though the company has not established a commercial geographic footprint.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.